Monkeypox dose sparing? Biden admin looks to NIH-funded study for clues.
The FDA is considering recommending dose-sparing of the monkeypox vaccine. It is using this 2015 study to back up a potential recommendation.
The Biden administration’s embrace of dose-sparing, an approach intended to stretch the limited supply of monkeypox vaccine doses
is partly based on a 2015 study funded by the National Institutes of Health, according to two senior administration officials.
The Food and Drug Administration said Friday it is considering dose-sparing as the administration grapples with how to contain
More than 7,500 Americans have been infected as of Friday, according to the Centers for Disease Control and Prevention.
The U.S. is running low on vaccine and dose sparing could offer public health officials a way to control
the spread of the virus while the federal government finds solutions for obtaining additional shots.
To help close this gap, we’re considering an approach for the current doses of Jynneos that would allow health care
providers to use an existing one-dose vial of the vaccine to administer a total of up to five separate doses
FDA Commissioner Robert Califf told reporters in a briefing last week, referring to the monkeypox vaccine.
The two administration officials, granted anonymity to speak freely about the administration’s thinking
said the National Institute of Allergy and Infectious Diseases is conducting a dose-sparing study of the Jynneos vaccine but that it could take months to complete